

Abstract

Disclosed is a pharmaceutical composition which comprises a disrupted cell suspension of *Monilia albicans* and euglobulin as effective ingredients. The euglobulin
5 is contained in the pharmaceutical composition in an amount of 10 to 250 mg per ml of the disrupted cell suspension *M. albicans*. Also, the present invention discloses a method of treating animals infected with canine distemper virus or animals with neurological disorders. The pharmaceutical composition has excellent therapeutic efficacy on animals with the canine distemper virus as well as animals with neurological
10 disorders.